Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
Do you recommend up-titrating the Metformin dose of patients with T2DM who are at goal A1c in order to decrease their risk of diabetes-related delirium?
Sun et al., PMID 39361020
Answer from: at Academic Institution
I have not been adjusting metformin based on delirium.
Sign in or Register to read more
28157
Related Questions
Outside of teplizumab, what therapies do you recommend for preserving beta cell function in patients with early stage type 1 diabetes mellitus?
Would you recommend the 1-hour OGTT over the 2-hour OGTT for postpartum glucose tolerance testing in women with previous gestational diabetes?
Should long-acting subcutaneous insulin be started upfront in addition to regular insulin infusion for patients with diabetic ketoacidosis?
How do you approach insulin adjustments for a patient with type 1 diabetes who is not on an insulin pump and who has higher blood glucose levels in the late luteal phase of the menstrual cycle, when glucose levels are expected to rise?
What is the preferred first-line non-insulin agent in patients with ketosis-prone diabetes during "remission" and evidence of preserved beta cell function?
Do you favor Sotagliflozin over SGLT2i alone for cardiovascular risk reduction in patients with Type 2 diabetes and chronic kidney disease?
Do you recommend avoiding the use of GLP-1 agonists in patients with a history of suicidal thoughts, given recent evidence showing an association with increased risks of psychiatric disorders, including depression and suicidal behavior?
Is the combination of SGLT2i and GLP 1 R agonist therapy contraindicated in patients who develop an episode of euglycemic DKA?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
How should diabetic retinopathy surveillance be adjusted for patients starting GLP-1 agonists?